Route 92 Medical Secures $100 Million Debt Facility

The neurovascular technology firm secured new funding to accelerate product innovation and commercial expansion.

Updated on Oct. 20, 2026 in Healthcare

Route 92 Medical Secures $100 Million Debt Facility

Live Poll

Do you believe large debt-financed expansions by medical tech companies generally improve patient care outcomes?

Route 92 Medical has entered into a $100 million senior secured debt facility provided by Trinity Capital. The company plans to use this capital to support continued product innovation and commercial growth for its neurovascular platforms.

Why it matters

The infusion of capital allows the company to accelerate the development and market adoption of its neurovascular systems, which include tools for treating large vessel occlusions.

Route 92 Medical holds more than 200 issued patents across the United States and international jurisdictions. The firm also utilizes FDA-cleared technology, such as the HiPoint 88, for the direct aspiration of large vessel occlusions.

The players

Route 92 Medical

This West Jordan-based company specializes in developing advanced neurovascular platforms for medical procedures.

Trinity Capital

This investment firm provides debt financing and operates across markets in the United States and Europe.

The details

Based in West Jordan, Utah, Route 92 Medical develops neurovascular platforms that integrate access, delivery, and control. Its Tenzing delivery catheters are designed to navigate complex neurovascular anatomy to treat patients.

October 20, 2026: Route 92 Medical announced the $100 million debt facility.

Market Landscape

This financing reflects the broader trend of medical technology firms leveraging debt facilities to scale specialized neurovascular interventions like the HiPoint 88. It positions Route 92 Medical to compete more aggressively in a market defined by rapid innovation in stroke treatment technology.

The expansion of Route 92 Medical may increase the availability of advanced stroke treatment technologies in hospitals served by the company. While this move does not directly change retail consumer costs, it signifies a broader push toward improving clinical outcomes for patients suffering from large vessel occlusions.

The takeaway

Securing significant debt financing allows medical device companies to maintain autonomy while scaling critical healthcare technologies. This trend highlights the importance of venture-backed innovation in bridging the gap between clinical research and widespread hospital adoption.